Technical Articles

This article systematically elucidates the molecular characteristics and clinical significance of KRAS G12V, one of the most common oncogenic mutations, detailing its high-frequency distribution in pancreatic cancer, colorectal cancer, and non-small cell lung cancer, as well as its mechanisms in driving tumorigenesis and progression. It also analyzes the challenges in developing traditional small-molecule drugs targeting this mutation.

The KRAS gene is one of the most frequently mutated oncogenes in human malignancies, with this mutation detected in approximately one in seven cancers.

The KRAS gene is one of the most commonly mutated oncogenes in lung cancer, discovered over two decades earlier than the EGFR gene. However, compared to the rapid development of EGFR-targeted therapies, targeted treatments for KRAS-mutated non-small cell lung cancer have long lagged behind.